Boston Scientific Q4 Adjusted EPS $0.55 Beats $0.51 Estimate, Sales $3.73B Beat $3.59B Estimate
Portfolio Pulse from Benzinga Newsdesk
Boston Scientific (NYSE:BSX) exceeded analyst expectations for Q4 with an adjusted EPS of $0.55, surpassing the estimate of $0.51, and reported sales of $3.73B, beating the $3.59B estimate. These figures represent a 22.22% increase in EPS and a 14.90% increase in sales compared to the same period last year.
January 31, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Boston Scientific reported a strong Q4 with earnings and sales surpassing analyst estimates, indicating robust financial health and potential for stock price appreciation.
Boston Scientific's better-than-expected Q4 earnings and sales are likely to instill confidence in investors and could lead to a short-term increase in stock price. The significant year-over-year growth in both earnings and sales suggests that the company is on a strong growth trajectory, which is typically rewarded by the market. Given that earnings reports are a key driver of stock price movement, the positive results could have a favorable impact on BSX shares in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100